Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1996 3
1997 1
1998 1
1999 1
2004 2
2010 3
2011 3
2012 6
2013 6
2014 4
2015 7
2016 7
2017 2
2018 4
2019 5
2020 5
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

60 results
Results by year
Filters applied: . Clear all
Page 1
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Among authors: eberlein c. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP. Steele CW, et al. Among authors: eberlein c. Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2. Cancer Cell. 2016. PMID: 27265504 Free PMC article.
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA. Eberlein CA, et al. Cancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13. Cancer Res. 2015. PMID: 25870145 Free PMC article.
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ. Ward RA, et al. Among authors: eberlein c. J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30. J Med Chem. 2013. PMID: 23930994
Genetic Cell-Surface Modification for Optimized Foam Fractionation.
Blesken CC, Bator I, Eberlein C, Heipieper HJ, Tiso T, Blank LM. Blesken CC, et al. Among authors: eberlein c. Front Bioeng Biotechnol. 2020 Oct 29;8:572892. doi: 10.3389/fbioe.2020.572892. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33195133 Free PMC article.
Environmentally Relevant Concentration of Bisphenol S Shows Slight Effects on SIHUMIx.
Schäpe SS, Krause JL, Masanetz RK, Riesbeck S, Starke R, Rolle-Kampczyk U, Eberlein C, Heipieper HJ, Herberth G, von Bergen M, Jehmlich N. Schäpe SS, et al. Among authors: eberlein c. Microorganisms. 2020 Sep 19;8(9):1436. doi: 10.3390/microorganisms8091436. Microorganisms. 2020. PMID: 32961728 Free PMC article.
60 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page